THE CATALYTIC IMPACT FOUNDATION (CIF)
VC Fund
New York, United States
THE CATALYTIC IMPACT FOUNDATION (CIF) is a VC fund in New York focused on Health Care and Biotechnology. The Catalytic Impact Foundation accelerates breakthroughs — championing extraordinary innovations, catalytic ideas, and, most importantly, visionary leaders. The Foundation aims to solve complex problems and accelerate innovations, alleviate human suffering, address inequities, and improve the quality of human life through disruptive and scalableprojects in the life sciences, education, inclusive entrepreneurship and global sustainability. The Foundation is a registered 501(c)(3) charitable organization incorporated in New York State.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries THE CATALYTIC IMPACT FOUNDATION (CIF) invests in
Stages THE CATALYTIC IMPACT FOUNDATION (CIF) invests in
Countries THE CATALYTIC IMPACT FOUNDATION (CIF) invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Health Care 28 (52%)
- Biotechnology 27 (50%)
- Medical 13 (24%)
- Therapeutics 10 (19%)
- Pharmaceutical 7 (13%)
Stage
- Venture - Series Unknown 15 (28%)
- Funding Round 8 (15%)
- Seed 7 (13%)
- Series A 7 (13%)
- Series B 7 (13%)
Country
- United States 42 (78%)
- India 1 (2%)
- Australia 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Rachel Butler
President
|
President | Total investments: 1 | Find email | |
|
Richard Lipkin
Co- Founder, Co-Chair
|
Co- Founder, Co-Chair | Total investments: 0 | Find email | |
|
Robert Wolk
Executive Board Chair
|
Executive Board Chair | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
FlourishFund is a digital platform that empowers and supports new and expecting families. The platform consists of two parts: a marketplace with evidence-based goods and vetted maternal wellness services and a funding mechanism for friends and families to contribute to a positive birth and parenting journey. | $5.7M / Seed / Mar 18, 2026 | |
|
|
Egal is a manufacturer of pads on a roll, a product that can be dispensed in every public stall as easily as toilet paper. | $4M / Series A / Jan 22, 2025 | |
|
|
The National Renewable Network is a linked network of solar and storage systems that transforms the way energy is supplied. | $6.6M / Venture - Series Unknown / Jan 17, 2024 | |
|
|
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between thescientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation. | $165M / Series C / Dec 12, 2023 | |
|
|
Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres. The company is headquartered in Mountain View, California. | Oct 11, 2023 | |
|
|
Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $1.4M / Seed / Jul 12, 2023 | |
|
|
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between thescientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation. | $108M / Series B / Mar 06, 2023 | |
|
|
Ceretype Neuromedicine is an AI-based fMRI brain biomarker technology to improve drug discovery and patient care. Based in Cambridge Massachusetts, Ceretype is founded on seminal scientific discoveries made in the laboratory of Emily Stern, David Silbersweig, and Hong Pan at Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS). | $100K / Pre-Seed / Mar 02, 2023 | |
|
|
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $25M / Series B / Jan 30, 2023 | |
|
|
Healthcare is too complex. We're here to make it simple. | Venture - Series Unknown / Jan 01, 2023 | |
| See all 54 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does THE CATALYTIC IMPACT FOUNDATION (CIF) invest in?
THE CATALYTIC IMPACT FOUNDATION (CIF) invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Funding Round stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact THE CATALYTIC IMPACT FOUNDATION (CIF)?
Public channels for THE CATALYTIC IMPACT FOUNDATION (CIF) include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at THE CATALYTIC IMPACT FOUNDATION (CIF)?
The team at THE CATALYTIC IMPACT FOUNDATION (CIF) includes Rachel Butler (President), Richard Lipkin (Co- Founder, Co-Chair) and Robert Wolk (Executive Board Chair). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!